P/B
0,9
Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
$232.6M
Market Cap • 9/22/2026
2015
(11 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
15,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
9,8
EPS
—
Market Cap
Market Cap
232,6M
EV
-9,3M
EV/Revenue
-0,6
EV/EBITDA
0,1
EV/EBIT
0,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
161,1%
Total Yield
161,1%
Payout
0%
Retained Earnings
-534,2M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
505,3%
Capex/Revenue
3,3%
Capex/D&A
30,9%
Capex/OCF
-1%
SBC/OCF
—
% PPE
6,7%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
12,4%
CAGR Net Income 5Y
8,9%
CAGR EPS 5Y
8,7%
CAGR OCF 5Y
0,4%
Leverage
N.D./EBITDA
2,4
Debt/Equity
0%
Current Ratio
22
Quick Ratio
21,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!